Estrella Immunopharma (ESLA) announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data ...
Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback